Involvement of Reticulum Endoplasmic Stress in the Physiopathology of Polycystic Ovary Syndrome

Polycystic Ovary Syndrome Clinical Trial

— PI12/1984  

Official title:

Involvement of Reticulum Endoplasmic Stress in the Physiopathology of Polycystic Ovary Syndrome: Possible Therapeutic Implications of Insulin Sensitizers.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02302326
• Other study ID #: AHM-MET-2013-01
• Status: Completed
• Phase: N/A
• Start date: January 2013
• Est. completion date: December 2019

Study information

• Verified date: February 2020
• Source: Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main objective of the present project is to evaluate the relevance of reticulum stress in the pathogenesis of polycystic ovary syndrome (PCOS), focusing particularly on the underlying mechanisms of insulin resistance, which is the origin of metabolic comorbidities. Furthermore, the investigators will assess the potential of insulin sensitizers as a treatment to control endoplasmic reticulum stress markers in PCOS patients.

Description:

To do this, the investigators will evaluate anthropometric, biochemical and hormone parameters, lipid profile and cardiovascular risk markers (using enzymatic and biochemical techniques, nephelometry, enzyme-linked immunosorbent assay, radioimmunoassay), and markers of endoplasmic reticulum stress and the insulin pathway and inflammatory and apoptotic parameters (by means of Western blot, Real Time- Polymerase Chain Reaction (RT-PCR), Luminex® xMAP® Technology ) in patients with and without PCOS. The investigators' second objective is to evaluate (using the abovementioned methodology) the efficacy of different insulin sensitizers (myoinositol and metformin) administered to PCOS patients during a 3-month period after which the investigators will analyze different parameters of oxidative stress and mitochondrial function (using Clark electrode and fluorometric techniques).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: December 2019
• Est. primary completion date: December 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Women diagnosed with PCOS using the Rotterdam criteria

• Women of reproductive age

Exclusion Criteria:

• Organic, malignant, haematological, infectious or inflammatory disease

• History of ischaemic heart disease (stroke or thromboembolism)

• Diabetes mellitus,

• Secondary causes of obesity (hypothyroidism, Cushing's syndrome)

• Severe hypertension.

• Smoking or alcohol habit

Related Conditions & MeSH terms

• Polycystic Ovary Syndrome
• Syndrome

Intervention

Drug:
• Metformin
Dose: metformin (1700 mg / day) for 12 weeks

Dietary Supplement:
• Myo-inositol + folic acid
Dose: Ovusitol® (4 g myo-inositol plus 400 micrograms of folic acid/day) for 12 weeks

Locations

Country	Name	City	State
Spain	Antonio Hernández	Valencia

Sponsors (1)

Lead Sponsor	Collaborator
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana

Country where clinical trial is conducted

Spain, 

References & Publications (3)

Hernández-Mijares A, Bañuls C, Gómez-Balaguer M, Bergoglio M, Víctor VM, Rocha M. Influence of obesity on atherogenic dyslipidemia in women with polycystic ovary syndrome. Eur J Clin Invest. 2013 Jun;43(6):549-56. doi: 10.1111/eci.12080. Epub 2013 Mar 26. — View Citation

Victor VM, Rocha M, Bañuls C, Alvarez A, de Pablo C, Sanchez-Serrano M, Gomez M, Hernandez-Mijares A. Induction of oxidative stress and human leukocyte/endothelial cell interactions in polycystic ovary syndrome patients with insulin resistance. J Clin Endocrinol Metab. 2011 Oct;96(10):3115-22. doi: 10.1210/jc.2011-0651. Epub 2011 Jul 21. — View Citation

Victor VM, Rocha M, Bañuls C, Sanchez-Serrano M, Sola E, Gomez M, Hernandez-Mijares A. Mitochondrial complex I impairment in leukocytes from polycystic ovary syndrome patients with insulin resistance. J Clin Endocrinol Metab. 2009 Sep;94(9):3505-12. doi: 10.1210/jc.2009-0466. Epub 2009 Jun 30. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in markers of endoplasmic reticulum stress in controls and pcos women before and after metformin/Myo-inositol + folic acid administration	Markers of endoplasmic reticulum stress (78-kDa glucose-regulated protein (GRP78), ubiquitous translation initiation factor 2a (eIF2a), double-stranded RNA-activated protein kinase (PERK), inositol requiring enzyme 1 (IRE1a), X-box binding protein 1 (XBP-1)) were assessed by Western Blot and Real Time- Polymerase Chain Reaction (RT-PCR) in polymorphonuclear cells	3 months
Primary	Changes in markers of the insulin pathway in controls and pcos women before and after metformin/Myo-inositol + folic acid administration	Markers of the insulin pathway (c-Jun N-terminal kinase (JNK), insulin receptor substrate (IRS)) were assessed by Western Blot and Real Time- Polymerase Chain Reaction (RT-PCR) in polymorphonuclear cells	3 months
Primary	Changes in inflammatory parameters in controls and pcos women before and after metformin/Myo-inositol + folic acid administration	Inflammatory parameters (nuclear factor ?B (NF-?B), interleukin-6 (IL6), tumor necrosis factor a (TNFa)) were assessed by Western Blot, Real Time- Polymerase Chain Reaction (RT-PCR), or Luminex® xMAP® Technology in polymorphonuclear cells and serum	3 months
Primary	Changes in apoptotic parameters in controls and pcos women before and after metformin/Myo-inositol + folic acid administration	Apoptotic parameters (transcription factor C/EBP homologous protein (CHOP) and caspase 12) were assessed by Western Blot and Real Time- Polymerase Chain Reaction (RT-PCR) in polymorphonuclear cells	3 months
Secondary	Changes in anthropometric parameters in controls and pcos women before and after metformin/Myo-inositol + folic acid administration	Anthropometric (weight, height, body mass index and waist) and blood pressure parameters were evaluated	3 months
Secondary	Changes in biochemical parameters in controls and pcos women before and after metformin/Myo-inositol + folic acid administration	Glucose levels were measured using enzymatic techniques. Insulin was measured by an enzymatic luminescence technique. IR was calculated by homeostasis model assessment (HOMA). Total cholesterol and triglycerides were measured by employing enzymatic assays, and high density lipoprotein cholesterol (HDLc) concentrations were recorded with an autoanalyser using a direct method. Low-density lipoprotein cholesterol (LDLc) concentration was calculated using the Friedewald method. Luteinizing hormone (LH), follicle stimulating hormone (FSH) and testosterone were measured by specific radioimmunoassays. Dehydroepiandrosterone-sulfate (DHEAS), sex hormone-binding globulin (SHBG), androstenedione and testosterone were measured by specific chemiluminescence techniques. High-sensitive C-reactive protein (hsCRP) was quantified by a latex-enhanced immunonephelometric assay	3 months
Secondary	Changes in mitochondrial function parameters in controls and pcos women before and after metformin/Myo-inositol + folic acid administration	Oxidative stress markers ( mitochondrial oxygen (O2) consumption, membrane potential, glutathione, reactive oxygen species (ROS) and hydrogen peroxide levels, mitochondrial mass) were assessed by Clark electrode and fluorometric techniques	3 months
Secondary	Changes in endothelial function parameters in controls and pcos women before and after metformin/Myo-inositol + folic acid administration	Interactions between leukocytes and human umbilical vein endothelial cells were evaluated by flow chamber microscopy (leukocyte rolling velocity, leukocyte rolling flux and leukocyte adhesion). The vascular cell adhesion molecule 1 (VCAM-1), Intercellular adhesion molecule 1 (ICAM-1) and E-selectin were evaluated in serum by Luminex® 200 flow analyzer system	3 months